Mylan struck by disappointing financial results for 2018

Shares in the Netherlands-incorporated generics drugmaker Mylan (Nasdaq: MYL) have suffered a near-10% hit in pre-market trading, following a disappointing financial results statement covering the final three months of 2018.

Total revenues were $3 billion, down 5% compared to the prior year period, with total revenues for 2018 coming in at $11 billion, down 4%.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share (EPS) figure was $0.10, down 78%. For the full year, the EPS figure was $0.68, down 47%.